Abstract

MB-73. CASE REPORT: MULTIPLE PILOMATRIXOMAS IN A SURVIVOR OF WNT1 MEDULLOBLASTOMA LEADING TO THE DISCOVERY OF A GERMLINE APC MUTATION AND THE DIAGNOSIS OF FAMILIAL ADENOMATOSIS POLYPOSIS Anne Bendel1, Mary Skrypek1, Melissa Hansen1, Amy Wein1, Mahmoud Nagib2, William McDonald3, and Dinel Pond1; Children’s Hospitals and Clinics of Minnesota, Minneapolis/St. Paul, MN, USA; Neurosurgical Associates, Minneapolis, MN, USA; Abbott Northwestern Hospital, Minneapolis, MN, USA Pilmatrixoma is a benign neoplasm that arises from hair matrix cells and usually occurs as a solitary lesion. Solitary pilomatrixoma frequently harbors activating mutations in the B-catenin gene, leading to inhibition of B-catenin degradation and accumulation of nuclear B-catenin, which activates the WNT pathway and drives tumor formation. Multiple pilomatrixomas are rare, but can be seen in several conditions including familial adenomatous polyposis (FAP). The APC gene product is important in ubiquitin-mediated degradation of B-catenin; therefore some mutations of APC interfere with B-catenin degradation resulting in WNT activation and tumor formation, including formation of pilomatrixoma, colon cancer and other WNT driven tumors. We describe the caseofan11-year-oldgirl whodeveloped multiplepilomatrixomas on her head, neck and trunk 3 years following the diagnosis and treatment of a WNT+ medulloblastoma. Her family medical history is unknown due to being adopted from the Philippines. Because of the known association of multiple pilomatrixomas and FAP, and the known association of medulloblastoma and FAP, she underwent genetic testing and was found to have a pathogenic germline mutation of the APC gene (c.595dupG (p.Ala199Glyfs*53)) which is consistentwithadiagnosis ofautosomaldominant familial adenomatouspolyposis. The patient will now undergo regular surveillance for FAP related cancers, which may be potentially lifesaving. This is the first reported case of multiple pilomatrixomas in association with medulloblastoma. Neuro-Oncology 18:iii97–iii122, 2016. doi:10.1093/neuonc/now076.69 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call